---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-109718"
form_type: "8-K"
ticker: "HUMA"
cik: "0001818382"
company_name: "Humacyte, Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:26:01.602604+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Humacyte Q3 2025 revenue $753K from Symvess launch; net loss narrows to $17.5M; raises $56.5M post-quarter

## Summary
- Total revenue $753K in Q3, all from Symvess sales; no revenue in Q3 2024.
- Net loss $17.5M in Q3 vs $39.2M in Q3 2024, improved on non-cash contingent earnout remeasurement.
- Cash $19.8M at Sep 30; subsequent $56.5M net proceeds from stock/warrant sale.
- Symvess: 25 VAC approvals (92 hospitals eligible); 16 hospitals ordered, majority re-orders.
- Pipeline: positive V007 2-year dialysis data; IND submitted for CABG; supplemental BLA planned H2 2026.

## SEC filing metadata
- accession: 0001104659-25-109718
- form_type: 8-K
- ticker: HUMA
- cik: 0001818382
- company_name: Humacyte, Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818382/000110465925109718/0001104659-25-109718-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818382/000110465925109718/tm2530973d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-109718
- JSON: https://secwatch.observer/filing/0001104659-25-109718.json
- Plain text: https://secwatch.observer/filing/0001104659-25-109718.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.